The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

Background: The Gustave Roussy Immune (GRIm)-Score takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) and its prognostic value has been investigated in patients treated with immune check-point inhibitors (ICIs). To further assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenci, Edoardo, Cantini, Luca, Pecci, Federica, Cognigni, Valeria, Agostinelli, Veronica, Mentrasti, Giulia, Lupi, Alessio, Ranallo, Nicoletta, Paoloni, Francesco, Rinaldi, Silvia, Nicolardi, Linda, Caglio, Andrea, Aerts, Sophie, Cortellini, Alessio, Ficorella, Corrado, Chiari, Rita, Di Maio, Massimo, Dingemans, Anne-Marie C., Aerts, Joachim G. J. V., Berardi, Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958321/
https://www.ncbi.nlm.nih.gov/pubmed/33801320
http://dx.doi.org/10.3390/jcm10051005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958321/
https://www.ncbi.nlm.nih.gov/pubmed/33801320
http://dx.doi.org/10.3390/jcm10051005

Ejemplares similares